Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
November 30, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, announced today it received an extension of 180 calendar days from the Nasdaq Stock Market...
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 18, 2022 17:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), today announced that, effective November 15, 2022, the independent directors approved equity awards under Nuwellis’ 2021...
Nuwellis, Inc. Reports Third Quarter 2022 Financial Results
November 08, 2022 08:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial...
Nuwellis Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using a Modified Aquadex in Low-Birth-Weight Preterm Neonates
November 03, 2022 07:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NasdaqCM: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the...
Nuwellis, Inc. To Announce Third Quarter 2022 Financial Results on November 8, 2022
October 19, 2022 16:15 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ: NUWE) announced today that its third quarter 2022 financial results will be released on Tuesday, November 8, 2022. The company...
Nuwellis Announces Appointment of Chief Financial Officer
October 19, 2022 07:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Continuing its commitment to expanding access to life-saving ultrafiltration therapies for adult and pediatric patients suffering from fluid overload,...
Nuwellis Announces Closing of $11.04 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
October 18, 2022 16:15 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) ("Nuwellis" or the "Company"), a commercial-stage company focused on transforming the lives of people with fluid...
Nuwellis Announces Pricing of $9.6 Million Upsized Underwritten Public Offering
October 14, 2022 08:30 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage company focused on transforming the lives of people with fluid...
Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality at the 2022 HFSA Meeting
October 03, 2022 07:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the results...
Nuwellis Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial
September 27, 2022 07:00 ET
|
Nuwellis, Inc.
MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the...